Table 1 Characteristics of female survivors of childhood cancer who developed subsequent breast cancers (N = 431)

From: Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer

Characteristic

N

% or median (IQR)

Primary cancer diagnosis

 Hodgkin lymphoma

251

57.9

 Leukemia

  Lymphoblastic leukemia

30

7.5

  Acute myeloid leukemia

14

3.2

  Other leukemia

3

0.7

 Sarcoma

  Soft tissue sarcoma

26

6.0

  Osteosarcoma

34

7.8

  Ewings sarcoma

23

5.3

  Other bone tumor

1

0.2

 Kidney tumor

19

4.4

 Non-Hodgkin lymphoma

18

4.2

 Neuroblastoma

5

1.2

 Central nervous system tumor

  Astrocytoma

6

1.4

  Medulloblastoma

1

0.2

Age at childhood cancer diagnosis (years)

431

15 (13-17)

Race

 White

412

95.6

 Non-White

19

4.4

Childhood cancer treatmenta

 Treated with chest radiotherapy

279

68.6

 Received anthracyclines

174

42.7

Other late chronic health conditions

 Major cardiovascular event before breast cancer

49

11.3

 Major cardiovascular event after breast cancer

35

8.1

 Subsequent malignancy before breast cancer

22

5.1

 Subsequent malignancy after breast cancer

36

8.3

Age at first breast cancer diagnosis (years)

431

40 (35-44)

Years between primary and breast cancer diagnosis

431

24 (19-29)

Breast cancer treatment era

 Before 2000

115

26.5

 2000-2009

186

42.9

 2010-2016

130

30.6

Subsequent breast cancer stageb

 0

101

26.3

 I

120

31.3

 II

112

29.9

 III

34

8.9

 IV

14

3.7

Breast cancer histologyb

 DCIS/LCIS only

101

23.5

 Invasive

326

76.5

Other breast tumor characteristicsc

 Progesterone receptor positive

215

66.9

 Estrogen receptor positive

266

77.7

 HER2 positive

64

25.8

Vital status

 Deceased

164

37.8

  1. CCSS Childhood Cancer Survivor Study, IQR interquartile range, PNET primitive neuroectodermal tumor, DCIS/LCIS ductal carcinoma in situ/lobular carcinoma in situ, HER2 human epidermal growth factor receptor 2.
  2. Missing childhood cancer treatment information: chest radiotherapy (n = 27), anthracyclines (n = 20).
  3. Missing breast cancer staging and histology: stage (n = 50), histology (n = 4).
  4. Missing breast tumor information: metastatic breast cancer (n = 27), progesterone receptor status (n = 112), estrogen receptor status (n = 88), HER2 receptor status (n = 186).